Protagenic Therapeutics, Inc.\new PTIX Cash Flow Statement (2013-2026)

OTC PTIX
$0.76 +0.01 (+1.33%)
At close: Oct 19, 2026 · 4:00 PM EDT
Reported Financials

Protagenic Therapeutics, Inc.\new Quarterly Cash Flow Statement

Periods 53 quarters
Latest Jun 2026

Protagenic Therapeutics, Inc.\new reported cash from operations of -$0.94M and free cash flow of -$0.94M for the quarter ended Jun 2026, up 46.1% year over year. This cash flow statement covers 53 quarters of results from Jun 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-0.88M-0.89M-1.36M-0.67M-0.93M-0.60M-0.72M-1.21M-1.40M-1.68M-1.72M-0.32M-0.58M-0.85M-1.44M-5.06M-0.87M2.21M5.08M-0.96M
Depreciation and DepletionDep. & Depletion
90.0091.000.00M0.03M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.10M0.05M0.03M0.03M0.03M0.03M0.02M0.03M0.03M0.01M0.24M1.32M
Depreciation & Amortization (CF)Dep. & Amort.
90.0091.000.00M0.03M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Share-based CompensationStock Comp.
0.23M0.22M0.24M0.22M0.21M0.20M0.17M0.17M0.17M0.17M0.16M0.27M0.25M0.25M0.24M0.13M0.11M0.10M0.09M0.07M
Gains from Investment SecuritiesGains Investment
0.00M-0.02M-0.01M-0.01M0.00M-0.12M-0.02M-0.48M-0.34M
Asset Writedowns and ImpairmentWritedown
0.01M
Other non-cash itemsOther Non-Cash
-0.02M2.13M-0.20M-3.11M0.79M
Change in Working Capital
Change in InventoryChange Inventory
57.00-20.00-1.00-10.00
Change in Account PayablesChange Payables
0.27M-0.44M0.39M0.83M0.05M
Change in Accured ExpensesChange Accured Exp.
0.14M0.10M-0.01M-0.32M0.09M0.15M0.11M0.12M-0.11M-0.30M-0.21M0.35M0.11M0.22M0.17M0.26M-0.10M-0.16M0.01M-0.01M
Change in Other Operating AssetsOther Assets Change
0.67M-0.11M-0.68M0.13M-0.04M-0.04M-0.04M0.86M-0.77M0.04M-0.10M0.40M-0.08M-0.32M0.01M0.07M-0.10M-0.05M-0.02M0.11M
Other Working Capital ChangesOther WC Changes
-0.67M0.11M0.68M-0.13M0.04M0.04M0.04M-0.86M0.77M-0.04M0.10M-0.40M0.08M0.32M-0.01M-0.07M0.10M0.05M0.02M-0.11M
Cash from OperationsCash from Ops.
-1.08M-0.41M-0.43M-0.85M-0.54M-0.18M-0.37M-1.53M-0.66M-1.14M-1.66M-1.55M-0.19M-0.82M-1.07M-1.75M-0.81M-0.51M0.27M-0.94M
Investing Activities
Capital ExpendituresCapex
0.09M
Change in Property, Plant and EquipmentChange in PP&E
-0.09M
Acquisitions
-0.94M
Net of Acquisitions & DivestmentsNet Acquisitions
0.94M
Purchase of InvestmentsInvestments Purchased
-0.07M2.75M0.30M
Sale and Maturity of InvestmentsInvestments Sold
0.37M0.71M0.46M0.09M0.29M1.61M0.66M5.12M1.50M1.60M
Cash from Investing ActivitiesCash from Investing
0.49M0.37M0.71M0.36M0.16M0.29M1.61M0.59M2.28M1.20M1.60M0.94M-0.31M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
0.87M0.08M-0.02M
Non-Current Debt
0.87M0.08M-0.02M
Short-Term Debt issuancesST Debt Issuance
Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
0.87M0.08M-0.02M
Change in Capital Stock
Common Stock IssuedStock Issued
0.32M1.60M0.10M4.35M2.00-2.00
Net Shares Issued and RepurchasedNet Shares Issued
0.32M1.60M0.10M4.35M2.00-2.00
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.32M1.60M0.10M4.35M2.00-2.00
Other financing activitiesOther financing
Cash from Financing ActivitiesCash from Financing
0.32M1.60M0.10M5.01M-0.60M-2.00-0.53M
Additional items
Exchange Rate EffectFX Effect
0.00M199.00806.000.00M0.00M0.08M467.00671.000.00M920.00190.00167.00-89.00399.00-11.00-0.12M0.04M-136.00-0.12M0.00M
Change in Cash
-11.47M0.08M-0.06M-0.14M-0.18M0.06M-0.08M0.08M-0.07M1.13M-0.46M0.09M0.13M0.78M-0.97M4.20M-1.41M-0.51M-0.58M-0.94M
Ending Cash Balance
0.46M0.54M0.48M0.34M0.16M0.22M0.14M0.22M0.15M1.29M0.00M0.92M0.07M0.08M0.01M4.10M2.72M2.21M1.51M0.57M
Free Cash FlowFCF
-1.08M-0.41M-0.43M-0.85M-0.54M-0.18M-0.37M-1.53M-0.66M-1.24M-1.66M-1.55M-0.19M-0.82M-1.07M-1.75M-0.81M-0.51M0.27M-0.94M
Net Cash FlowNCF
-1.08M0.08M-0.06M-0.14M-0.18M-0.02M-0.08M0.08M-0.07M1.13M-0.46M0.05M0.13M0.78M-0.97M4.20M-1.41M-0.51M-0.58M-0.94M

Protagenic Therapeutics, Inc.\new Cash Flow Statement API

Pull Protagenic Therapeutics, Inc.\new's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PTIX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY